

## SAFETY DATA SHEETS

**This SDS packet was issued with item:**

078948832

**The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).**

078948822 078948824 078948829 078948831 078948833

# Material Safety Data Sheet

## Gabapentin Tablet

Strength: ~~600/300~~ mg.

Pack Size: 100/500/~~1000~~ Tablets per bottle (for ~~600~~ mg)

Revision No.: 00

100/300/400

100/500/~~1000~~ and unit dose blister cartons of 100(10X10) unit dose Tablet/bottle(for 800mg)

Capsules 100/300/400


### EMERGENCY OVERVIEW

Gabapentin Tablets contain Gabapentin and excipients generally considered to be non- toxic and non-hazardous in small quantities and under conditions of normal occupational exposure.

### Section 1. Identification of the substance

#### Identification of the product

Product name: Gabapentin Tablet  
Formula:  $C_9H_{17}NO_2$   
Chemical Name: 1-(aminomethyl)cyclohexanecarboxylic acid  
Therapeutic Category: Antiepileptic



Gabapentin

#### Manufacturer / supplier identification

Company: Cadila Healthcare Ltd. Ahmedabad, India  
Contact for information: Tel.: +91 79 6868100 Fax: +91 79 3750319  
Emergency telephone No. Tel.: +91 79 6868100

### Section 2. Composition / information on ingredients

Component	Exposure Limit	CAS No.
<b>Principle Component :</b>		
Gabapentin	Not Found	60142-96-3
<b>Inactive ingredients :</b>		
Copovidone	Not Found	9003-39-8
Low substituted hydroxypropyl cellulose	Not Found	9004-64-2
Magnesium stearate	Not Found	577-04-0
Mannitol	Not Found	69-65-8
Poloxamer	Not Found	106392-12-5
Talc	Not Found	14807-96-6

# Material Safety Data Sheet

## Gabapentin Tablet

Strength: ~~600/800~~ mg.

Pack Size: 100/500/1000 ~~Tablets~~ per bottle (for ~~600~~ mg)

Revision No.: 00

100/300/400

100/500/1000 and unit dose blister cartons of 100(10X10) unit dose Tablet/bottle(for 800mg)

Povidone

Not Found

9003-39-8

### Section 3. Health Hazards Information

#### Dose and Administration

**Capsules**  
Gabapentin ~~tablets~~ are given orally with or without food. Patients should be informed that, should they break the scored 600 or 800 mg tablet in order to administer a half-tablet, they should take the unused half-tablet as the next dose. Half-tablets not used within several days of breaking the scored tablet should be discarded.

**Capsules**  
If gabapentin ~~tablets~~ dose is reduced, discontinued or substituted with an alternative medication, this should be done gradually over a minimum of 1 week (a longer period may be needed at the discretion of the prescriber).

#### Adverse Effects

##### Postherpetic Neuralgia:

**Capsules**

The most commonly observed adverse events associated with the use of gabapentin ~~tablets~~ in adults, not seen at an equivalent frequency among placebo-treated patients, were dizziness, somnolence, and peripheral edema.

##### Epilepsy:

**Capsules**

The most commonly observed adverse events associated with the use of gabapentin ~~tablets~~ in combination with other antiepileptic drugs in patients >12 years of age, not seen at an equivalent frequency among placebo-treated patients, were somnolence, dizziness, ataxia, fatigue, and nystagmus. The most commonly observed adverse events reported with the use of gabapentin tablets in combination with other antiepileptic drugs in pediatric patients 3 to 12 years of age, not seen at an equal frequency among placebo-treated patients, were viral infection, fever, nausea and/or vomiting, somnolence, and hostility

Adverse events following the abrupt discontinuation of gabapentin have also been reported. The most frequently reported events were anxiety, insomnia, nausea, pain and sweating.

#### Over Dose Effect

**Capsules**  
Acute oral overdoses of gabapentin ~~tablets~~ up to 49 grams have been reported. In these cases, double vision, slurred speech, drowsiness, lethargy and diarrhea were observed. All patients recovered with supportive care.

#### Medical Conditions

Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements.

**Capsules**  
Taking gabapentin ~~tablets~~ with certain other medicines can cause side effects or affect how well they work. Do not start or stop other medicines without talking to your healthcare provider.

Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine.

#### Contraindications

**Capsules**  
Gabapentin ~~tablets~~ are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients.



**Material Safety Data Sheet**  
**Gabapentin Tablet**

Strength: ~~600/800~~ mg.

Pack Size: 100/500/~~1000~~ ~~Tablets~~ per bottle (for ~~600~~ mg)

Revision No.: 00

**100/300/400**

100/500/~~1000~~ and unit dose blister cartons of 100(10X10) unit dose Tablet/bottle(for 800mg)

**Capsules 100/300/400**

**Pregnancy Comments** There are no adequate and well- controlled studies in pregnant women. This drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

**Pregnancy Category** C

**Section 4. First aid measures**

**General**

**Inhalation**

Remove to fresh air. If not breathing give artificial respiration. If breathing is difficult, give oxygen. Seek medical attention.

**Contact with skin**

Immediately wash skin with soap and copious amounts of water for at least 15 minutes. If irritation persists, seek medical attention.

**Contact with eyes**

Immediately flush eyes with copious amounts of water for at least 15 minutes. Seek medical advice

**Ingestion**

If swallowed, wash out mouth with water, provided person is conscious. Seek medical advice

Remove and wash/dispose of contaminated clothing promptly.

**Overdose Treatment**

Gabapentin can be removed by hemodialysis. Although hemodialysis has not been performed in the few overdose cases reported, it may be indicated by the patient's clinical state or in patients with significant renal impairment.

**Section 5. Fire – fighting measures**

**Flash point**

Not Found

**Upper Flammable Limit:**

Not Found

**Auto-Ignition Temperature:**

Not Found

**Lower Flammable Limit:**

Not Found

**Extinguishing Media**

Water Spray, dry chemical, carbon dioxide or foam as appropriate for surrounding fire and material.

**Fire and Explosion Hazard**

This material is assumed to be combustible.  
As with all dry powders it is advisable to ground mechanical equipment in contact with the dry material to dissipate the potential build up of static electricity.

**Fire Fighting Procedure**

As with all fires, evacuate personnel to a safe area. Fire fighter should use self- contained breathing equipment and protective clothing.

# Material Safety Data Sheet

## Gabapentin Tablet

Strength: ~~600/300~~ mg.

100/300/400

Pack Size: 100/500/1000 ~~Tablets~~ per bottle (for ~~600~~ mg)

Capsules 100/300/400

Revision No.: 00

100/500/1000 and unit dose blister cartons of 100(10X10) unit dose Tablet/bottle(for 800mg)

### Section 6. Accidental Release Measures

#### Spill Response

Wear approved respiratory protection, chemically compatible gloves and protective clothing. Wipe up spillage or collect spillage using high efficiency vacuum cleaner. Avoid breathing dust. Place spillage in appropriately labelled container for disposal. Wash spill site.

### Section 7. Handling and Storage

#### Storage

Store at 20° to 25° C (68° to 77° F). Dispense in a tight container.

### Section 8. Exposure controls and personal protection

#### Respiratory Protection

Protection from inhalation is not normally necessary. If ventilation is inadequate or dust is likely to generate, use of suitable dust mask would be appropriate.

#### Skin Protection

Skin protection is not normally necessary, however it is good practice to avoid contact with chemical to use suitable gloves when handling.

#### Eye protection

Eye protection is not normally necessary. If concerned wear protective goggles or glasses. Wash hands prior to touching eye and in particular handling contact lenses.

#### Protective Clothing

Protective clothing is not normally necessary, however it is good practice to use apron.

### Section 9. Physical and chemical properties

#### Appearance

~~Gabapentin Tablets, 600mg~~ Capsules 100/300/400 are white to off-white, oval-shaped, biconvex, film-coated tablets debossed with 'ZE72' with bisect on one side and plain with bisect on other side

~~Gabapentin Tablets, 800mg~~ Capsules 100/300/400 are white to off-white, oval-shaped, bevelled-edge, biconvex, film-coated ~~tablets~~ debossed with 'ZE71' with bisect on one side and plain with bisect on other side

#### Solubility in water

Freely soluble

#### Odour

Odourless

#### Boiling point

No Data Available

#### Melting Point

No Data Available

#### Evaporation rate

No Data Available

#### Vapour density

No Data Available

#### Reactivity in water

No Data Available

#### Evaporation rate

No Data Available

#### Percentage Volatile by volume

No Data Available

#### Specific gravity

No Data Available

#### Vapour pressure

No Data Available

#### Other information

Not Applicable

### Section 10. Stability and Reactivity



**Material Safety Data Sheet**  
**Gabapentin Tablet**

Capsules

100/300/400

Strength: ~~600/300~~ mg.

Pack Size: 100/500/~~1000~~ Tablets per bottle (for ~~600~~ mg)

Revision No.: 00

100/300/400

100/500/~~1000~~ and unit dose blister cartons of 100(10X10) unit dose Tablet/bottle(for 800mg)

<b>Condition to avoid</b>	Avoid exposure to extreme heat, light and moisture.	<b>Stable</b>	Stable under normal ambient and anticipated storage and handling conditions.
<b>Decomposition Products</b>	No Data Available	<b>Hazardous Reaction</b>	No data available.
<b>Incompatibilities</b>	No data available.		

**Section 11. Toxicological information**

<b>General</b>	Handling of formulated product is not expected to cause any toxicological affects. The data pertains to the ingredient in formulations, rather than this specie formulation.
<b>Target organ</b>	Eye contact, Skin contact and inhalation is not great risk as this product is tablet.
<b>Other</b>	Not Applicable

**Section 12. Ecological information**

No data available on Ecotoxicity

**Section 13. Disposal Consideration**

<b>Disposal</b>	Dispose the waste in accordance with all applicable Federal, State and local laws.
-----------------	--

**Section 14. Transport Information**

May be shipped normally as a non hazardous material.

**Section 15. Regulatory Information**

Generic Medicine. Approved by USFDA & the ANDA Number is 40663

**Section 16. Other information**

None

**Date of issue:** 13/07/2012

**Supersedes edition of:** New Edition

The information contained herein is based on the state of our knowledge. It Characterises the product with regard to the appropriate safety precautions. It does not represent a guarantee of the properties of the product.